Third Rock Thinks Its Model Reassures Investors In Difficult Times

Market turmoil and declining valuations in biotech are not deterring Third Rock Ventures from doing what it has done since 2007: raising funds of increasing size to back new biotechs that it incubates internally. Partner Abbie Celniker explained to Scrip that the venture capital firm’s long-term planning, and having long-term investors, makes it less susceptible to market conditions.

On 15 June, the Boston-based venture capital firm announced it has raised $1.1bn, its biggest fund to date and one...